Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21waf1/cip1 expression

Cancer Science

Volumn 101, Issue 6, 2010, Pages 1424-1430

  Noro, Rintaro ^a   Miyanaga, Akihiko ^a   Minegishi, Yuji ^a   Okano, Tetsuya ^a   Seike, Masahiro ^a   Soeno, Chie ^a   Kataoka, Kiyoko ^a   Matsuda, Kuniko ^a   Yoshimura, Akinobu ^a   Gemma, Akihiko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CYCLIN DEPENDENT KINASE INHIBITOR 1; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDYLATE SYNTHASE; VORINOSTAT;

ARTICLE; CANCER CELL; CANCER GROWTH; CYTOTOXICITY; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DRUG COMBINATIONS; E2F1 TRANSCRIPTION FACTOR; FLUOROURACIL; GENE EXPRESSION REGULATION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; LUNG NEOPLASMS; OXONIC ACID; RETINOBLASTOMA PROTEIN; RNA, MESSENGER; TEGAFUR; THYMIDYLATE SYNTHASE;

EID: 77954146994     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01559.x     Document Type: Article

References (41)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995, 311:899-909.
2. Sandler AB, Nemunaitis J, Denham C. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000, 18:122-30.
3. Shepherd FA, Dancy J, Ramlau R. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-103.
4. Hanna N, Shepherd FA, Fossella FV. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-97.
5. Shephered FA, Rodrigues Pereira J, Ciuleanu T. National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-32.
6. Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002, 1:287-99.
7. Kelly WK, Richon VM, O'Connor O. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 2003, 9:3578-88.
8. Kelly WK, O'Connor OA, Krug LM. Phase I Study of an Oral Histone deacetylase inhibitor, Suberoylanilide hydroxamic acid, in Patients with advanced cancer. J Clin Oncol 2005, 23:3923-31.
9. Rubin EH, Agrawal NG, Friedman EJ. A study to determine the effects of food and multiple dosing on the pharmacokinetics of vorinostat given orally to patients with advanced cancer. Clin Cancer Res 2006, 12:7039-45.
10. Duvic M, Talpur R, Ni X. Phase II trial of oral vorinostat (SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 1:109.
11. Miyanaga A, Gemma A, Noro R. Anti-tumor activity of Histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 2008, 7(6):1923-30.
12. Kim MS, Black M, Baek JH, Kohlhagen G, Pommier Y, Carrier F. Inhibition of histone deacetylase increases cytotoxicity to anti-cancer drugs targeting DNA. Cancer Res 2003, 63:7291-300.
13. Jang ER, Lim SJ, Lee ES. The histone deacetylase inhibitor inhibitor trichostatin A sentitizes estrogen receptor α-negative breast cancer cells to tamoxifen. Oncogene 2003, 23:1-13.
14. Marchion DC, Bieaku E, Daud AI, Richon V, Sullivan DM, Munster PN. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid. J Cell Biochem 2004, 92:223-37.
15. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 1993, 5:4004-9.
16. Nakano J, Huang C, Liu D. Evaluation of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer 2006, 95:607-15.
17. Inoue K, Takao M, Watanabe F. Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small-cell lung cancer-incorrelation with the tumoral expression of thymidylate synthase and dihydropyrmidine. Lung Cancer 2005, 49(1):47-54.
18. Peters GJ, van Groeningen CJ, Laurensse EJ, Piendo HM. Sensitivity of human, murine, and rat cells to 5-FU and 57-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986, 46:20-8.
19. Huang CL, Yokomise H, Fukushima M, Kinoshita M. Tailor-maid chemotherapy for non-small cell lung cancer patients. Future Oncol 2006, 2(2):289-99.
20. Peters GJ, van der Wilt CL, van Triest B. Thymidylate Synthase and drug resistance. Eur J Cancer 1995, 31(A):1299-305.
21. Rustum YM, Harstrick A, Cao S. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1997, 15:389-400.
22. Saga Y, Suzuki M, Mizukami H. Overexpression of Thymidylate synthase mediates desensitization for 5-fluorourai of tumor cells. Int J Cancer 2003, 106:324-6.
23. Kawahara M, Furuse K, Segawa Y. S-1 Cooperative Study Group (Lung Cancer Working Group). Phase II study S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001, 85:939-43.
24. Ichinose Y, Yoshimori K, Sakai H. S-1 plus cisplatin combination chemotherapy in patients with advanced non-small-cell lung cancer: a multi-institutionl Phase II trial. Clin Cancer Res 2004, 10:7860-4.
25. Gemma A, Takenaka K, Hosoya Y. Altered expression of several genes in highly metastatic subpopulations of a human pulmonary adenocarcinoma cell line. Eur J Cancer 2001, 37(12):1554-61.
26. Wang W, Cassidy J, O'Brien V, Ryan KM, Collie-Duguid E. Mechanistic and predictive profiling of 5-FU resistance in human cancer cells. Cancer Res 2004, 64:8167-76.
27. Noro R, Gemma A, Kosaihira S. Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation. BMC Cancer 2006, 6:6.
28. McMillan RE, Sikes ML. Differential activation of dual promoters alters Dβ2 germline transcription during thymocyte development. J Immunol 2008, 180:3218-28.
29. van Groeningen Cees J, Peters Godefridus J, Schornagel Jan H. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000, 18:2772-9.
30. Okano T, Gemma A, Hosoya Y. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer. Oncol Rep 2006, 15:545-9.
31. Lu X, Errington J, Curtin NJ, Lunec J, Newell DR. The impact of p53 status on cellular sensitivity to antifolate drugs. Clin Cancer Res 2001, 7:2114-23.
32. Chu E, Callender MA, Farell MP, Schmitz JC. Thymidylate synthase inhibitors as anticancer agents: from bench to bed side. Cancer Chemother Pharmacol 2003, 52(Suppl):S80-9.
33. Welsh SJ, Titley J, Brunton L. Comparison of Thymidylate synthase (TS) protein up-regulation after TS inhibitor in normal and tumor cell lines and tissues. Clin Cancer Res 2006, 6:2538-46.
34. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP. Human Ovarian Carcinoma cells: histone deacetylase inhibitors exhibit anti-proliferative activity and potently induce apoptosis. Cancer 2004, 101(12):2760-70.
35. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21 expression and gene-associated histone acetylation. Pro Natl Acad Sci 2000, 97(18):10014-9.
36. Banerjee D, Gorlick R, Liefshitz A. Levels of E2F1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase. Cancer Res 2000, 60:2365-7.
37. Kasahara M, Takahashi Y, Nagata T. Thymidylate synthase expression correlates closely with E2F1 expression in colon cancer. Clin Cancer Res 2000, 6:2707-11.
38. Huang CL, Liu D, Nakano J. E2F1 overexpression correlates with thymidylate synthase and surviving gene expressions and tumor proliferation in non-small-cell lung cancer. Clin Cancer Res 2007, 13(23):6938-46.
39. Banerjee D, Schnieders B, Fu JZ, Adhikari D, Zhao SC, Bertino JR. Role of E2F1 in Chemosensitivity. Cancer Res 1998, 58:4292-6.
40. DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis and G1/S regulatory genes. Mol Cell Biol 1995, 15:4215-24.
41. Di Gennaro E, Bruzzese F, Pepe S. Modulation of thymidylate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5-FU or raltitrexed. Cancer Biol Ther 2009, 8(9):782-91.